AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX207.73-3.98 (-1.88%) ▼|SBUX106.25-1.60 (-1.48%) ▼|SCHW109.82-0.34 (-0.31%) ▼|SO88.00-0.25 (-0.28%) ▼|SPG212.32-2.24 (-1.04%) ▼|T25.89-0.12 (-0.46%) ▼|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN260.91+2.27 (+0.88%) ▲|UBER75.65-3.17 (-4.02%) ▼|UNH389.41-3.54 (-0.90%) ▼|UNP300.67-5.32 (-1.74%) ▼|UPS104.23-1.10 (-1.04%) ▼|USB61.58-0.89 (-1.42%) ▼|V379.37-2.23 (-0.58%) ▼|VZ50.02-0.08 (-0.16%) ▼|WFC86.39-0.30 (-0.35%) ▼|WMT104.87+1.78 (+1.73%) ▲|XOM160.95+4.24 (+2.71%) ▲|AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX207.73-3.98 (-1.88%) ▼|SBUX106.25-1.60 (-1.48%) ▼|SCHW109.82-0.34 (-0.31%) ▼|SO88.00-0.25 (-0.28%) ▼|SPG212.32-2.24 (-1.04%) ▼|T25.89-0.12 (-0.46%) ▼|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN260.91+2.27 (+0.88%) ▲|UBER75.65-3.17 (-4.02%) ▼|UNH389.41-3.54 (-0.90%) ▼|UNP300.67-5.32 (-1.74%) ▼|UPS104.23-1.10 (-1.04%) ▼|USB61.58-0.89 (-1.42%) ▼|V379.37-2.23 (-0.58%) ▼|VZ50.02-0.08 (-0.16%) ▼|WFC86.39-0.30 (-0.35%) ▼|WMT104.87+1.78 (+1.73%) ▲|XOM160.95+4.24 (+2.71%) ▲|
22 C
New York
Tuesday, September 1, 2026

Tag: retina

newssourceFORcompanyinformationcontent1releasesmarket

G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise

"Highlighting Strategic Alliances and Innovation, the Global GPCR Targeting Market Report Explores the Role of GPCRs in Drug Discovery and Therapeutics, Featuring Key Players...

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa

First modules of BLA submitted to FDA under rolling review, with full submission anticipated in early 2026MCO-010 BLA for retinitis pigmentosa is eligible for priority review...

NextRise 2025 Held in Seoul, Asia’s Leading Innovation Expo Co-hosted by KITA and KDB

- Over 3,600 one-on-one meetups conducted between 250 corporates/investors and 1,100 startups from 28 countries - - Germany, this year's featured country, dispatched official delegation;...

Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating time to potential approval

Lifeforce and Toku Combine AI Retinal Scans with the World’s Largest Longevity-Medicine Platform to Take Steps to Slow Aging and Reduce Cardiovascular Risk

SANTA MONICA, Calif., July 7, 2025 /PRNewswire/ -- Lifeforce, the world's largest longevity medicine platform, and Toku, a health technology company using AI to...

First patient dosed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRetina

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers